In recent days, the escalation of the situation in Russia and Ukraine has begun to have an impact on the global agricultural trade pattern. Ukraine is one of the main source countries of my country's corn imports. According to customs data, in 2021, my country will import 8.24 million tons of corn from Ukraine, accounting for 29.07%. At present, Ukraine has closed port operations. Before there is no clear sign of easing the conflict between the two countries, it is expected that the overall international corn price will remain strong, which will push up the cost of imported corn in my country.

    With the gradual start of resumption of work and production, some enterprises will start a new round of replenishment during the period from late February to early March. The demand for new purchases will increase moderately, and the market transaction volume will gradually increase. It is expected that from late February to early March, the main The price of corn in the production area is mainly weak at first and then strong, and the monthly average price in February is basically stable and slightly down.

    Toltrazuril is a triazinone compound, which is a new type of broad-spectrum anticoccidial drug. Toltrazuril is a white or almost white crystalline powder; it is odorless. Dissolved in ethyl acetate or dichloromethane, slightly soluble in methanol, insoluble in water. It was successfully developed by the German Bayer company in the 1980s. It has broad-spectrum anticoccidial activity and can effectively kill many protozoa including Eimeria, among which are tender, pile-shaped, giant, poisonous, Brinell, etc. The 6 species of Eimeria have high-efficiency killing effects and belong to highly effective anti-coccidial drugs. Because of their good insecticidal effect, low toxicity, and wide anti-coccidial range, they are widely used in chicken coccidiosis all over the world. Toltrazuril has a wide range of sites for coccidia, and it has effects on both asexual cycles of coccidia, such as inhibiting schizonts, the nuclear division of the small gametophyte, and the wall forming body of the small gametophyte. Toltrazuril interferes with the nuclear division and mitochondria of coccidia, affects the respiratory and metabolic functions of the parasite, and can enlarge the endoplasmic reticulum of the cell and cause severe cavityization, so it has the effect of killing coccidia.

    98% of 500 kg toltrazuril powder is available in stock, the price is favorable, welcome to consult.

    Entering November, the continued strong veterinary drug raw materials market lacked stamina, market demand has been weak, and the volume has decreased. In view of the current high prices, the downstream wait-and-see atmosphere has become increasingly strong, and procurement is cautious. Although the trading center of the entire market is still strong, However, the momentum was not enough, and the prices of some products that rose rapidly in the early stage fell back from high levels.

    On the 3rd, the price index of veterinary medicine raw materials (VPi) closed at 101.26, down 1.12%, and the index has fallen for the first time since September.

//Florfenicol

    On the 3rd, the average market price of florfenicol was 708 yuan/kg, a decrease of 2.75% from the previous month and an increase of 54.58% year-on-year. The price of florfenicol was still at a historical high.

    At present, florfenicol manufacturers have stable shipments, high-level shipments at the intermediate trade level, and obvious intention to withdraw funds. Market supply has increased, downstream procurement is cautious, the contradiction between supply and demand has eased slightly, and product prices have fallen from high levels. However, with the arrival of winter, the prices of upstream raw materials such as bromine may rise seasonally, and the cost will support florfenicol. Although florfenicol is expected to decline, it will continue to operate at a relatively high historical level in the short term.

//Doxycycline hydrochloride

    On Wednesday, the average market price of doxycycline hydrochloride was 710 yuan/kg, down 3.01% month-on-month and up 1.72% year-on-year.

    In recent years, insufficient supply has always revolved around doxycycline hydrochloride, and this is also true for the large-scale increase in doxycycline hydrochloride. Although the price of doxycycline hydrochloride has fallen this time, compared with the normal period, the manufacturers are still running short and the supply problem is still not effectively solved. Doxycycline hydrochloride may continue to be high in a short period of time.

    Previously, under the influence of multiple factors such as the energy consumption dual control policy, the veterinary raw material drug market saw a large general rise. However, during this cycle, the veterinary raw material drug market has slowed down, and individual products have been sorted out and trended. Differentiation.

   // VPi's rise is slowing down

    On the 27th, the price index of veterinary raw materials (VPi) closed at 102.41, an increase of 0.68% from the previous month. The index reached a new high this year. The increase of VPi in this period was significantly slower than that in early October.

  //Trend differentiation

    This week, a significant change in the veterinary raw material drug market was the differentiation of product trends. Most varieties remained strong and prices continued to rise, but the average market prices of a few varieties saw a slight correction.

    Tiamulin, which has been stable recently, has the largest increase this week, up 3.39% month-on-month. Methaquine, Tylosin tartrate and Tilmicosin continued their previous trends, and prices continued to rise, setting a new high for the year.

    It is important to note that in the early stage, the price of doxycycline hydrochloride, which was continuously strong in the early stage, and ran at a high price, experienced a callback for the first time after a lapse of two months. Analysts believe that mainstream manufacturers are gradually resuming production, operating rates have rebounded, and market supply has increased. Under the situation of relatively weakening supply and demand pressures, the average market price of doxycycline hydrochloride may continue to adjust.

    On the whole, the current veterinary drug raw materials market price has been operating to a high level in recent years. Driven by factors such as dual control and cost, the strong veterinary drug raw materials market may continue in the short term, but the increase is expected to narrow compared with the previous period. Some products After the supply tension is relatively easing, it may fall back at a high level.

    Raw materials for veterinary drugs: The recent market performance of raw materials for veterinary drugs has been eye-catching. Categories such as florfenicol, doxycycline hydrochloride, and quinolones have been affected by rising production costs at the factory and limited production capacity, and their prices have risen sharply and become more popular. Tylosin, tilmicosin, colistin, methaquine and other categories followed closely. After a period of sorting, news has been released recently to show their willingness. The overall price performance of the veterinary drug raw material market has become stronger, and from the analysis of the recent supply capacity of the factory supply, it may continue to operate strongly in a short period of time.

    Vitamins: The domestic vitamin market is generally stable. The factory side has obvious willingness to stand up prices. Affected by the dual control of energy consumption and rising raw material costs, inquiries for VK3, VD3, VE and other categories are active, taking advantage of the price increase, and the transaction is good; the overall consumption speed of the middle and downstream markets is not good, and the inventory digestion speed is slow. Slower, lower profits, mostly wait-and-see.

Veterinary medicine raw material market analysis

Broad-spectrum antibiotic penicillins:

Penicillin industrial salt-the quotation of mainstream factories continues to be high, trade channels are actively building positions, low-priced sources are snapped up in the market, market expectations are good (the transaction is 99-105 yuan/billion), and the market price index is running at a high level.

Amoxicillin - Affected by factors such as production capacity and production costs, the quotations of mainstream factories continue to be high (transactions of 190-198 yuan/kg), and the market price index fluctuates at a high level in this period.

Amido alcohols:

Florfenicol--Recently affected by high upstream raw material prices and production capacity, mainstream factories are willing to raise prices, supply is limited, market stocks are quickly digested, prices rise rapidly (transactions are 620-640 yuan/kg), and the market price index is high Strong operation.

Tetracyclines:

Oxytetracycline and oxytetracycline hydrochloride-mainstream factories offer high prices, relatively concentrated supply, stable market transactions, and little market trends. The current market price index remains stable (Oxytetracycline transaction 80-88 yuan/kg, oxytetracycline hydrochloride 100-105 yuan/kg).

Doxycycline hydrochloride (doxycycline)--mainstream factories released news about suspension of supply, reporting, and maintenance. The shortage of goods in the market continued, the market demand was relatively stable, and the market trade price was high and strong (transactions were 670-685 yuan/kg) .

Macrolides:

Erythromycin thiocyanate-the quotation of mainstream factories is high, and the domestic and foreign markets are highly concerned (the transaction is at 360-375 yuan/kg). The market price index in this issue is running steadily and continues to be concerned.

Tylosin, Tilmicosin, Tylosin - The quotations of mainstream factories in the early stage have increased, the mid- and downstream markets have responded positively, and the low-priced inventory of trade channels has been consumed rapidly. The transaction price of Jiutai is around 290 yuan/kg, phosphatid is around 390 yuan/kg, tilmicosin is around 445 yuan/kg, tyvanin is around 775 yuan/kg, and tiamulin is around 290-300 yuan/kg). Mainstream factories released news of production suspension and reporting, and continued to pay attention to the information of upstream factories' signing and quotation.

Aminoglycosides:

Streptomycin sulfate-the market supply is relatively concentrated, the quotations of mainstream factories are high, the recent market transactions are average, and the market price index is running at a high level (transactions at 250-285 yuan/billion).

The supply of apramycin sulfate is normal in mainstream factories, and the factories lowered their quotations. The mid- and downstream markets followed suit. The actual transaction volume did not change much (recently 220-230 yuan/kg), and the market price index was weak.

Neomycin sulfate--mainstream factories have released news of suspension of production and reporting, and the market is paying attention to the follow-up progress on the production side. The market price index in this period has stabilized (transactions at 140-150 yuan/billion).

Gentamicin Sulfate--mainstream factories for veterinary products have concentrated sources of supply, factory quotations are high, market inquiries are mainly negotiated (veterinary products are sold at 1390-1410 yuan/billion), the market price index fluctuates to maintain stability, pay attention to mainstream factories The message is released.

Sulfonamides:

The upstream supply of sulfonamides is relatively concentrated, the prices of main upstream raw materials are high, the supply of factories is insufficient, and the market price index is slightly strong. Pay attention to it. (Sulfachloropyridazine sodium is near 335 yuan/kg, sulfachloropyrazine sodium is near 355 yuan/kg, and sulfamonomethoxine sodium is near 340 yuan/kg)

Quinolones:

Enrofloxacin and ciprofloxacin--mainstream factories have concentrated supply, upstream raw material prices are high, factory prices have risen, market expectations are better, and the overall price performance is firm (enno and ciprofloxacin traded at 227-235 yuan/kg) , The market price index is running at a high level.

Vitamin market analysis

VA: The quotations of mainstream factories have always been higher than the market transaction prices. The mid- and downstream markets have a strong wait-and-see atmosphere, low willingness to open positions, and the overall market demand is general. The bargaining transaction is mainly (trade transaction price 270-285 yuan/kg), and there is no shortage of low-priced goods in the market. , The market price index fluctuated and sorted out.

VE: Mainstream factories have released news about production suspension and maintenance. Domestic and foreign inquiries have increased and the attention has been paid. Price negotiation (market quotation 77-80 yuan/kg), the volume and price of the mid- and downstream markets have stabilized slightly, and the market price index has stabilized.

Calcium pantothenate: The domestic market demand is not good, but due to rising factory production costs, factory quotations are driven (market quotation 71-75 yuan/kg), market attention increases, low-priced sources decrease, and market price indices fluctuate to maintain stability.

Niacinamide: The price of upstream raw materials has risen, mainstream factories are willing to increase prices, and the market is highly concerned (market quotation 52-55 yuan/kg), but the transaction is average and the market price is broad. The market price index in this period has maintained stable operation.

VD3: Mainstream factories increased their quotations (market quotations of RMB 93-100/kg), and their willingness to ship goods decreased, which led to active market inquiries, but actual transactions did not increase significantly. The market was mainly on the sidelines, and the market price index rose slightly.

VB1: Mainstream factories stop production and reform, market inquiries are active, market transactions are not good, the current market price index remains stable and weak (traders quoted at 145-155 yuan/kg), mainly negotiated transactions.

VB2: Some factories have raised prices and limited sales (80% of the products are quoted in the market at 85-90 yuan/kg), but the supply side is relatively scattered, low-priced inventory is abundant in the early stage, market transactions are not good, and the market price index maintains stable operation.

VB6: Market procurement is stable, trade quotations are broad (market quotations 120-125 yuan/kg), and the market price index remains stable.

VB12: The recent market transactions are not good (market price 130-135 yuan/kg), the market price index remains stable at a low level, the market capacity is relatively scattered, and the upward pressure on prices is greater.

2% Biotin: The recent market performance has been flat. The market has low-priced inventory and supply. Due to the pressure of inventory and expiration, the market transaction price is weak and stable (market price 55-60 yuan/kg).

Folic acid: Cost impact, driven by export prices, increased market attention, domestic bargaining transactions are mainly (market quotation 250-275 yuan/kg), and the market price index maintains stable operation.

VK3: Upstream raw material prices have increased, cost pressures have increased, some factories have raised prices slightly, market attention has increased (market price 70-77 yuan/kg), and the market price index has risen.

VC: The epidemic is under control, domestic supply is gradually loosening, mid-upstream and upper quotations are loose (market quotation 40-46 yuan/kg), and the market price index is running weakly.

Amino acids

Lysine: The factory delivery is still tight, and the transaction has been stable recently. Some factories have stopped reporting. 70% of the products are quoted at 6.3-6.8 yuan/kg, and 98% of the products are quoted at 9.1-9.8 yuan/kg. The market has recently been in a wait-and-see state, in a balanced position, waiting to move from time to time, pay attention to the factory's resumption of production, shipments and quotations.

Methionine: The market price is 18.5-20.0 yuan/kg. The overall market demand is average, the domestic factory supply is slow, the market inquiries are active, and the market price index has risen slightly. The factory side is very price-conscious, pay attention to the news of mainstream factory quotations.

Threonine: The market price is 11.2-12.2 yuan/kg. The quotations in the domestic and foreign markets are stable this period, the mainstream factories have limited delayed supply, the market inquiries are frequent, and the market price index remains stable.

Raw materials for veterinary drugs: The market for raw materials for veterinary drugs is stable in this period. The mainstream supply of veterinary drug raw materials is still underperforming compared to the past, and mainstream factories have to perform more contracts, and it is difficult to restore normal supply levels in a short time. The prices of most common supplies have been realized at a high level and remain stable. At the same time, they are in the post-holiday breeding market recovery stage. The downstream demand is general. With the consumption of early-stage inventory in the middle and lower reaches, market inquiries and purchases will gradually increase. If the supply from upstream factories has not been significantly eased, it is expected to maintain a high level for a period of time. Recently, we will focus on quinolones, dimenidazole, methaquine and other categories.

Vitamins: The vitamin market has been stable recently. The market has been affected by the increase in the price of chemical products. Some factories of related categories have raised relevant quotations. However, the transaction volume has not broken through this period. The downstream demand is blocked by the recovery process of pig production capacity. Most purchases are made with small and medium-sized orders, and rational bargaining is the main focus. The range of low prices has gradually moved up, and there is a strong wait and see atmosphere. It is expected that the vitamin category will show a trend of differentiation according to the degree of production capacity dispersion, and the market will continue to maintain a fierce competition stage.

In recent years, African swine fever has been like a "storm" that has reshaped the global pork market and has had varying degrees of impact on the business of global pork suppliers.

According to data released by the German Pig Association, there are currently hundreds of thousands of pigs in the country's farms, and each livestock will cost local farmers about 60 euros (about 469 yuan). To make matters worse, if there is no financial assistance from the local government, there will be a large number of farmers facing the risk of bankruptcy.

What happened to the German pork industry?

From the current point of view, the German pork industry is facing two major "heavy mountains": Covid-19 and African Swine Fever.

According to ISN data, based on market prices, the lockdown measures to control the Covid-19 directly caused 1.3 billion euros (approximately RMB 10.1 billion) in losses to the German pig industry, and German farmers suffered heavy losses.

This is mainly due to the prevention of the spread of the Covid-19. Germany not only reduced the number of orders from restaurants, but also forced German slaughterhouses to reduce production capacity. As a result, there was a backlog of pigs in German pig farms.

What makes the situation worse is that African Swine Fever has also put pressure on German pig farmers and further reduced their income.

According to incomplete statistics, since the outbreak of ASF in Germany on September 10, there have been 114 confirmed wild boar cases in Germany so far.

Taking into account safety issues, Asian countries such as China, Japan, and South Korea have successively announced bans on the import of German pork, which has also caused serious setbacks for the country’s pork export industry. According to a report on November 23, affected by the reduction in imports of German pork in the Asian market, the price of live pigs in Germany has fallen by more than 40% compared with March.

In the end, according to ISN forecasts, this year, affected by the above two factors, the total loss of the German pig industry is 1.5 billion euros (about 11.7 billion yuan).

It is worth mentioning that China is the “biggest gold owner” of the German pork export industry. Statistics show that China imports about 500 million euros (about 3.9 billion yuan) of German pork every year, but it has already banned the import of German pork.

       Brother Technology: Brother Technology (002562) released its third quarter report in the evening. In the first three quarters of 2020, the company achieved operating income of 1.421 billion yuan, a year-on-year increase of 58.16%; net profit attributable to shareholders of listed companies was 102 million yuan, a year-on-year increase of 429.97% .

　　 Zhejiang Medicine: On the evening of October 22, Zhejiang Medicine issued a third-quarter results announcement stating that in the first three quarters of 2020, the company achieved revenue of approximately 5.430 billion yuan, a year-on-year increase of 2.07%; net profit was approximately 621 million yuan, a year-on-year increase of 72.30%.

　　 Shengda Biology: Shengda Biology disclosed its third quarterly report, operating income for the first three quarters of 2020 was 666,879,888.27 yuan, a year-on-year increase of 78.35%, and the net profit attributable to listed companies was 200406148.72 yuan, a year-on-year increase of 348.8%.

        Garden Biology: Garden Biology (300401.SZ) released a report for the third quarter of 2020. The company’s operating income for the third quarter of 2020 was 145 million yuan, a year-on-year decrease of 9.33%; the net profit attributable to shareholders of listed companies was 6381.8 Ten thousand yuan, a year-on-year decrease of 19.51%.

Xinhecheng: Xinhecheng issued a third-quarter results announcement stating that in the first three quarters of 2020, the company achieved revenue of approximately 7.473 billion yuan, a year-on-year increase of 28.95%; net profit was approximately 2.937 billion yuan, a year-on-year increase of 72.52%; basic earnings per share 1.37 yuan, a year-on-year increase of 73.42%.

　　 Guangji Pharmaceutical: According to the announcement, the company’s operating revenue for the first three quarters was RMB 512,925,865.11, a year-on-year decrease of 7.64%, and the net profit attributable to shareholders of the listed company was RMB 47,818,949.90, a year-on-year decrease of 54.11%.

        Adisseo: Operating income in the first three quarters of 2020 was 8.881 billion yuan, a year-on-year increase of 6.8%, net profit attributable to the parent was 1.098 billion yuan, a year-on-year increase of 35.3%, and net profit attributable to the parent after deduction was 1.113 billion yuan, a year-on-year increase 64.0%.